Sign in

CIK 0001737287 · Non-accelerated filer<br>Smaller reporting company

Allogene Therapeutics, Inc.

Sign in to watch
Ticker
ALLO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
operating
EIN
823562771
Phone
(650) 457-2700
Business address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
  1. S-8 Other Securities Offered to Employees in Benefit Plans
  2. S-3 Offering Registration Statement
  3. 10-K Report Annual Report
  4. POSASR Other POSASR
  5. 144 Insider Sale of Securities
  6. 8-K Event Results of operations
  7. 10-K/A Report 10-K/A
  8. 4 Open-market buy CHIEF FINANCIAL OFFICER bought 190 shares at $3.60 ($683)
  9. UPLOAD Other SEC-generated Letter
  10. CORRESP Other Correspondence Between Filers and SEC Staff
  11. 8-K Event Restatement
  12. SC 13G/A Stake Amended Statement of Ownership
  13. SC 13G/A Stake Amended Statement of Ownership
  14. SC 13G/A Stake Amended Statement of Ownership
  15. SC 13G/A Stake Amended Statement of Ownership
  16. 4 Grant or award Chief Technical Officer acquired 96,600 shares (grant or award)
  17. 4 Grant or award SVP, General Counsel acquired 41,800 shares (grant or award)
  18. 4 Grant or award CHIEF FINANCIAL OFFICER acquired 29,400 shares (grant or award)
  19. 4 Grant or award Director acquired 211,973 shares (grant or award)
  20. 4 Grant or award EVP of R&D acquired 140,000 shares (grant or award)

Page 11 of 30 · 587 filings